Fallopian tube cancer
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- A primary or metastatic malignant neoplasm that affects the fallopian tube. Representative examples include carcinoma, carcinosarcoma, and leiomyosarcoma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Fallopian tube cancer
- Therapeutic area
- Oncology
- fallopian tube cancer
- tumor of the fallopian tube
- tumour of the fallopian tube
- cancer of fallopian tube
- cancer of fallopian tubes
- fallopian tube cancer
- fallopian tube malignant neoplasm
- fallopian tube malignant tumor
- fallopian tube malignant tumour
- malignant fallopian tube neoplasm
- malignant fallopian tube tumor
- malignant fallopian tube tumour
- malignant neoplasm of fallopian tube
- malignant neoplasm of the fallopian tube
- malignant neoplasm of uterine tube
- malignant tubal tumor
- malignant tubal tumour
- malignant tumor of fallopian tube
- malignant tumor of fallopian tubes
- malignant tumor of the fallopian tube
- malignant tumour of fallopian tubes
- malignant tumour of the fallopian tube
- neoplasm, fallopian tube, malignant
- tubal cancer
- tumor, fallopian tube, malignant
- Severity
- Severe
- Oncology
- Reproductive Health
- MONDO ID
- MONDO:0002158
- Parent condition
- MONDO:0001416
Related records
Broader conditions (16)
- Cancer
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Fallopian tube disorder
- Fallopian tube neoplasm
- Female reproductive organ cancer
- Female reproductive system disorder
- Female reproductive system neoplasm
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Reproductive system cancer
- Reproductive system disorder
- Reproductive system neoplasm
Narrower conditions (15)
- Cancer of isthmus of fallopian tube
- Fallopian tube adenocarcinoma
- Fallopian tube adenosarcoma
- Fallopian tube carcinoma
- Fallopian tube carcinosarcoma
- Fallopian tube clear cell adenocarcinoma
- Fallopian tube endometrioid adenocarcinoma
- Fallopian tube gestational choriocarcinoma
- Fallopian tube leiomyosarcoma
- Fallopian tube mucinous adenocarcinoma
- Fallopian tube papillary adenocarcinoma
- Fallopian tube serous adenocarcinoma
- Fallopian tube squamous cell carcinoma
- Fallopian tube transitional cell carcinoma
- Hereditary fallopian tube carcinoma
Trials (532)
- "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
- A Beta-only IL-2 ImmunoTherapY Study
- A Biomarker Screening Protocol for Participants With Solid Tumors
- A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
- A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer
- A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer
- A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
- A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
- A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer
- A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer
- A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
- A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.
- A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
- A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers
- A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy
- A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
- A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
Approved drugs (1)
Drugs in development (151)
- Abagovomab Phase 1
- Adavosertib Phase 2
- Aldesleukin Phase 2
- Alemtuzumab Phase 1
- Alisertib Phase 2
- Allopurinol Phase 2
- Alvimopan Phase 3
- Amifostine Phase 2
- Atezolizumab Phase 3
- Atrasentan hydrochloride Phase 2
- Avelumab Phase 1
- Baloramotide Phase 1
- Belinostat Phase 2
- Bicalutamide Phase 2
- Binimetinib Phase 3
- Birinapant Phase 2
- Canfosfamide hydrochloride Phase 2
- Capecitabine Phase 2
- Carboplatin Phase 3
- Carboxyamidotriazole Phase 2
Other linked drugs (2)
- Catequentinib
- Niraparib tosylate monohydrate